drugset / Trial / NCT04088292

Low Dose Thrombolysis, Ultrasound Assisted Thrombolysis or Heparin for Intermediate High Risk Pulmonary Embolism

NCT04088292

RandomizedParallel-groupSingle-blindTreatment

Summary

Open label clinical randomized trial comparing three strategies for managing acute intermediate-high risk pulmonary embolism

Timeline

Start
2019-06-06
Primary completion
2024-06-05
Completion
2024-11-30

Drugs

EvaluationDrugModalityDoseRoute
Comparator Alteplase Protein / enzyme biologic 20 mg Intravenous

Indications